Here are the 10-Q quarterly reports from AI Technology Group Inc (AIPG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIPG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIPG filings page.
AI Technology Group Inc. filed an amended Form 10‑Q for the quarter ended September 30, 2025, mainly to state on the cover that it is a non‑shell company. The business generated no revenue and recorded a net loss of $29,628 for the quarter and $33,889 for the nine months, compared with a nine‑month loss of $1,962 a year earlier. As of September 30, 2025, it reported $989 of prepaid expenses, $76,165 in current liabilities, and a stockholders’ deficit of $75,176, and disclosed substantial doubt about its ability to continue as a going concern.
The company has 1,603,413 common shares outstanding and is funded by related‑party advances, including $20,644 from its CEO during the nine months. On July 29, 2025, control shifted to a company controlled by Marcus Johnson, who became CEO and CFO. A prior error in classifying expenses and equity for 2024 led to restated figures. Subsequent to the quarter, on October 7, 2025, the company issued 27,958,695 restricted common shares to Biomed360 Solutions Corp. shareholders under a pending acquisition agreement, and management reported material weaknesses in internal controls over financial reporting.
AI Technology Group Inc. filed its quarterly report for the period ended September 30, 2025, showing no revenue and a net loss of $29,628 for the quarter and $33,889 year‑to‑date. Operating costs were primarily professional and listing fees. The company reported a working capital deficit of $75,176, with total current liabilities of $76,165 and no cash on hand.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern and concluded disclosure controls and procedures were not effective due to material weaknesses. Shares outstanding were 1,603,413 as of September 30, 2025. A change in control occurred on July 29, 2025, with new leadership assuming CEO and CFO roles.
Subsequent to quarter‑end, the company issued 27,958,695 restricted common shares to Biomed360 Solutions Corp. shareholders under a definitive agreement, while a contemplated acquisition of AVM Biotechnology remains subject to customary closing conditions. The company also restated certain 2024 balances to correct a material error, reclassifying items to prepaid expenses and equity.